Tag: Gilles Della Corte

Company News: Anergis to Present Three Scientific Posters at 34th European Academy of Allergy and Clinical Immunology (EAACI) Congress 2015

Anergis, a company developing novel and proprietary ultra-fast allergy immunotherapeutics, will present three scientific posters at the 34th European Academy of Allergy and Clinical Immunology (EAACI) Congress 2015 (Barcelona, June 6-10, 2015). All posters will focus on Anergis´ birch pollen immunotherapeutic AllerT, featuring detailed clinical data as well as in vitro and in vivo safety and immunogenicity data. AllerT is Anergis´ most advanced product and based on the company´s proprietary Contiguous Overlapping Peptide (COP) platform.


The following scientific communications will be presented at the EAACI Conference 2015:

Presentation Title: “Phase IIb follow-up trial of sustained efficacy of AllerT allergy vaccine during a second birch pollen season”

Presenter: Gilles Della Corte

Time and Date: Sunday, June 7, 2015, at 02:06pm CET

Session: Oral Abstract Session OAS 10 AIT: Efficacy and clinical outcomes

Abstract #: 327


Presentation Title: Persistence of anti-Bet v 1 IgG4 prior and during a second pollen season after AllerT ultra-fast immunotherapy (phase IIb follow up)”

Presenter: Dr. Christophe Reymond

Time and Date: Tuesday, June 9, 2015, at 10:30am CET

Session: Poster Discussion Session PDS 25: Immunotherapy vaccines

Abstract #: 530


Presentation Title: “Requirement for aluminium hydroxide as adjuvant for successful ultra-fast immunotherapy with AllerT”

Presenter: Dr. Alexander Kettner

Time and Date: Monday, June 8, 2015, at 12:00pm CET

Session: Thematic Poster Session TPS 32: Allergen standardization

Abstract #: 1141

Company News: Anergis Expands Management Team

– Company Appoints Gilles Della Corte as Director of Clinical Development and Eva Castagnetti as Director of Product Development –

Anergis, a company developing breakthrough allergy vaccines for fast and safe allergen-specific immunotherapy, today announced the expansion of its management team. With the appointments of Gilles Della Corte as Director of Clinical Development and Eva Castagnetti as Director of Product Development, the company has significantly strengthened its late-stage drug development expertise.

Gilles Della Corte, MD, brings to Anergis extensive expertise in global clinical development. In the past 22 years, he worked both for pharmaceutical companies, including Rhone-Poulenc Rorer, Servier, Solvay Pharma, Serono and Merck Serono, and for CROs where he held various senior positions in Research and Development. He has significant experience with all stages and aspects of clinical drug development ranging from Phase I to Phase IV. A cardiologist and pharmacologist by training, Gilles also holds diplomas in statistics and clinical trial methodology.

Eva Castagnetti, PhD, has several years of experience in both technical and business management  functions in the biopharmaceutical industry with Lonza, Senn Chemicals and Rapid Pharmaceuticals. She has been responsible for the development and production of Active Pharmaceutical Ingredients (peptides) in early to late clinical phases, gaining comprehensive experience of the regulatory and quality requirements in the development of new pharmaceutical products. Eva obtained her PhD in organic chemistry in 2001 from the University of Lausanne/EPFL and spent two years as a postdoctoral fellow at the Massachusetts Institute of Technology (Cambridge/Boston) and at the ETH Zurich.